Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Brain test could match PTSD veterans to the right medication

NCT ID NCT06852469

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study investigates whether a clinical test using lorazepam (Ativan) and brain imaging can identify veterans with PTSD who might benefit from medications that boost GABA signaling. Researchers aim to validate a computational method to distinguish subgroups of PTSD patients based on anxious arousal. The study involves 150 veterans, some with PTSD and some without, who will take either lorazepam or a placebo and perform motor tasks while their brain activity is measured.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Lorazepam (Ativan)
What this could lead to
If successful, this could lead to a simple test that helps doctors match the right PTSD medication to each veteran, improving treatment outcomes.
What could go wrong
This is a small, early-phase study focused on validating a test, not on treatment itself. The test may not prove reliable, and results may not apply to all PTSD patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Jun 2029

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a US federal agency other than the NIH.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Inclusion Criteria: 1. Veteran; 2. 18-65 years of age, inclusive; 3. Participants must be willing to abstain from alcohol 24 hours prior to and 24 hours after the testing session; 4. Participants must be able to participate and willing to give written informed consent and to comply with the study restrictions; Additional Inclusion Criteria for PTSD Group: (a) Current diagnosis of PTSD based on CAPS-5. Exclusion Criteria: Exclusion Criteria: 1. Has uncontrolled, clinically significant neurologic (including seizure disorders), cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal, urologic, immunologic, endocrine disease, or psychiatric disorder, or other abnormality, which may impact the ability of the subject to participate or potentially confound the study results; 2. Pregnancy (assessed by urine test at time of screening and prior to administration of study medication) or lactation; 3. Lifetime history of a chronic psychotic disorder or bipolar disorder type I as assessed by MINI; 4. Current moderate or severe substance use disorder as assessed by MINI; 5. Positive urine toxicology (drugs of abuse as determined by a positive urine test) at screening and before drug administration. Subjects who screen positive for THC will be given an opportunity to be included in the event of a negative urine test 2 weeks later. THC is not infrequently used for medicinal purposes and, in California, is legal for recreational use. Subjects who are positive for THC will therefore not be excluded, but will be retested to ensure that THC is unlikely to be influencing results; 6. Self-report or observable signs of drug or alcohol intoxication or withdrawal; 7. Current benzodiazepine or opioid use; other psychotropic medications are allowed as long as they are at a stable dose for at least 2 weeks and do not exhibit an unsafe interaction with the study medication; 8. Current or recent use of any medication deemed by the study physician (Dr. Howlett) to exhibit an unsafe interaction with lorazepam; 9. Past intolerance (including allergic) to lorazepam or another benzodiazepine; 10. Active suicidal ideation or otherwise considered at high suicidal risk by trained study staff using the C-SSRS; 11. History of a traumatic brain injury (TBI) resulting in loss of consciousness for more than 30 minutes; 12. Volunteers who do not have sufficient command of the English language, or who have any other impairment that would prevent them from reading and understanding the informed consent form(s) and completing the study procedures including clinical testing; 13. Any other reason why, per study physician, the subject should not participate in this study, including concomitant disease or condition that could interfere with, or for which the study drug might interfere with, the conduct of the study, or that would, in the opinion of the study physician, pose an unacceptable risk to the subject in this study. Additional Exclusion Criteria for HC Group: (a) Axis I disorder as assessed by MINI. Additional Exclusion Criteria for fMRI Participants: 1. Contraindication to magnetic resonance imaging. 2. Not right-handed as assessed by Edinburgh Handedness Inventory.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Stress disorders, post-traumatic are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • VA San Diego Healthcare System, San Diego, CA

    RECRUITING

    San Diego, California, 92161-0002, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.